Statolon, an interferon inducer, when instilled intranasally (IN) protects mice infected with lethal doses of influenza virus via the same route 16 hr later. The existence of interferon has been demonstrated in the trachea and lungs of mice treated IN with statolon, and it is assumed that the protection observed is due to this inhibitor. A dose response is seen with statolon administered IN. The protective activity of statolon instilled IN prophylactically lasts 1 to 2 weeks against influenza virus. Repeated doses of statolon, as many as four, a week apart, are effective. Antigenicity of the statolon (mycophage) particle relative to neutralization of its interferon-inducing capacity, therefore, may not prove to be a problem in clinical testing of this type of interferon inducer. The observed duration of activity of statolon also eliminates the possibility of difficulty due to hyporeactivity of the inducer.Once a viral infection is established, it is difficult to overcome with interferon inducers. Such inducers are more effective when administered prophylactically. A preferential route for administration of such inducers would be the intranasal (IN) route, a common portal of entry for many viruses. The fact that viruses are airborne even for relatively long distances (7) emphasizes the desirability of protection via this route.We have found that one prophylactic dose of statolon, an interferon inducer derived from Penicilliwn stoloniferwn, has a protective duration of activity of 30 days against MM virus in mice (11). Statolon administered prophylactically IN 16 hr before infection has also been found to protect mice against influenza virus inoculated via the same route (8). Because viruses have varying susceptibilities to interferon, determination of the duration of activity of statolon, instilled IN, against this respiratory virus was of interest relative to clinical application.Prophylactic use of an inducer invokes the necessity of repeated doses of the inducer. The double-stranded ribonucleic acid (DS-RNA)-containing mycophage particles (2,9,10), the predominant factor in statolon responsible for activity, are antigenic. A second dose of statolon could then be precluded from inducing interferon due to neutralization by antibody. The response to repeated doses of statolon has, therefore, been studied.MATERIALS AND METHODS Statolon. Statolon preparations similar to those previously described were employed (8,11,12). The statolon was dissolved in water. Concentrations of active statolon are based on nondialyzable solids.Treatment and infection of mice. Statolon in a volume of 0.05 ml, containing 300 ,g of the inducer, was administered with a syringe onto the noses of mice (ND4 strain, SPF), 11 to 13 g in weight, under light ether anesthesia. Control mice were treated with a saline solution. Sixteen hours later, the mice were infected with 10 LI),1 units of mouse-adapted PR8 influenza virus by aerosol. Infection was accomplished with a Tri-R aerosol infection apparatus capable of delivering aerosol particles appr...